Invention:
This technology is directed to a method of treating heart failure with preserved ejection fraction (HFpEF) by using a compound that mimics the effect of titin phosphorylation at the N2B segment. This technology has the potential to discover drugs for treating heart failure patients with stiff hearts and declined filling capacity.
Background:
About half of all heart failure patients suffer from excessive cardiac stiffness, which limits the heart’s ability to fill properly. There is a pressing need for therapies that reduce this stiffness, yet none currently exist. Titin plays a major role in determining the heart’s diastolic elasticity, and numerous studies show that increasing titin phosphorylation can decrease its passive stiffness. This makes targeting titin phosphorylation a promising strategy for improving cardiac filling in these patients.
Applications:
- HFePF therapeutics
- HFePF drug discovery
- High throughput biosensor assay
Advantages:
- High throughput
- Lower heart stiffness and improve filling capacity
- Expansion into veterinary care
